Igantibe

Human Hepatitis B Immunoglobulin, the active ingredient in Igantibe, is an immunoglobulin presented as a solution for injection for intramuscular use. It provides passive immunity to prevent hepatitis B infection in individuals at risk, such as after exposure or following liver transplantation.

GNH USA supplies Igantibe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Igantibe is a hepatitis B immune globulin used to prevent infection by supplying anti‑HBs antibodies.

- Post‑exposure prophylaxis of hepatitis B: reduces the risk of infection after accidental or occupational exposure to hepatitis B virus. - Prevention of hepatitis B recurrence after liver transplantation: helps maintain viral suppression in transplant recipients. - Prevention of hepatitis B infection in newborns of HBV‑positive mothers: provides passive immunity to infants at birth.

Igantibe may cause a range of adverse reactions following intramuscular administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: transient low‑grade temperature elevation. - Headache: mild to moderate headache after dosing.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Serum sickness‑like reaction: fever, rash, arthralgia occurring days after administration. - Severe hypersensitivity: urticaria, angioedema, or bronchospasm.

Before using Igantibe, consider the following safety measures.

- Assess HBV serostatus: confirm patient’s hepatitis B infection or exposure status. - Check for hypersensitivity: avoid in individuals with known allergy to human immunoglobulins. - Avoid in severe IgA deficiency: risk of anaphylactic reactions. - Monitor for infection signs: observe for fever, rash, or respiratory symptoms after injection. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Igantibe can interact with other agents that affect immune response or vaccine efficacy.

Major Interactions (Avoid): - Live attenuated vaccines: may reduce vaccine effectiveness; avoid concurrent administration. - Immunosuppressive therapy: may diminish passive immunity benefits.

Moderate Interactions (Monitor Closely): - Blood products containing anti‑HBs: potential additive antibody effect. - Antiviral agents for hepatitis B: monitor for overlapping immunologic effects. - Other immunoglobulin preparations: assess cumulative antibody load.